IPO
Evommune Files for IPO to Fund Phase 2 Trials of Autoimmune Drug Candidates
Evommune; IPO; Phase 2 trials; autoimmune drugs; EVO756; EVO301; chronic inflammatory diseases; biotech funding; New York Stock Exchange; Series C financing
Big Pharma-Backed MapLight Plots IPO to Advance Neuro Pipeline
MapLight Therapeutics; IPO; neuro pipeline; Alzheimer’s disease psychosis; schizophrenia; M1/M4 muscarinic agonist; Series D financing; Morgan Stanley; biopharmaceutical; clinical trials
LB Pharmaceuticals Upsizes IPO to $285M, Marks First Major Biotech Listing in Months
LB Pharmaceuticals; IPO; biotech; $285 million; LBRX; schizophrenia; Phase III; public offering; Nasdaq; 2025 biotech IPOs
LB Pharmaceuticals Raises $285M in Upsized IPO to Fund Late-Stage Schizophrenia Drug Development
LB Pharmaceuticals; IPO; schizophrenia; LB-102; amisulpride; Phase 3 clinical trial; bipolar depression; biotech fundraising; CNS drugs; FDA approval
LB Pharmaceuticals Files for $228M IPO to Fund Phase III Schizophrenia Drug
LB Pharmaceuticals; IPO; Phase III trial; schizophrenia; LB-102; biotech; CNS therapeutics; bipolar depression; Alzheimer’s psychosis; amisulpride; FDA; Nasdaq
CNS Pharmaceuticals Pursues Public Offering to Fund Phase 2 GBM Trial After Cost Cuts
CNS Pharmaceuticals; biotech; layoffs; IPO; public offering; phase 2 trial; glioblastoma multiforme; funding; cash position
Odyssey Therapeutics Abandons IPO Plans in Latest Sign of Tough Environment for Biotech Listings
Odyssey Therapeutics; IPO; biotech; withdrawal; SEC; market turbulence; autoimmune
Three-Month Drought in U.S. Biotech IPOs: Recent Developments and Context
biotech IPO; biotech market; IPO drought; 2025; biotech fundraising; biotech stocks
Chronic care startup Omada Health files to go public
Chronic care management, virtual care, IPO, digital health, diabetes management, cardiometabolic health, hypertension, musculoskeletal conditions, revenue growth, Hinge Health
DualityBio Pursues $200M IPO in Hong Kong Amid Volatile Market Conditions
DualityBio, IPO, Hong Kong Stock Exchange, biotech investment, antibody-drug conjugates, BioNTech, market upheaval, global trade tensions, biotech sector growth.